Developmental Research Program

RPCI-UPCI卵巢癌孢子的发展研究计划是一个平台，支持创新的、潜在高风险/高回报的、研究者发起的项目，这些项目有可能成熟为转化卵巢癌研究项目，将基础和/或人群研究成果转化为专注于人类临床标本/患者群体的研究。此外，发展研究计划的资金将通过鼓励将试点项目发展为合作的、多研究者的、多机构的转化研究项目，或替代RPCI-UPCI卵巢癌孢子的个人研究项目来加以利用。因此，发展研究计划项目是SPORE成功的最终衡量标准，并形成了个别机构未来转化卵巢癌研究的基础，因为它们是下一代R01， P01，财团和SPORE资助的跳板。来自已建立卵巢癌研究项目的教师，或对卵巢癌转化研究感兴趣的教师的提案，将由执行委员会根据科学价值进行评估。发展研究项目负责人将召开NIH格式研究部分，并将NIH R21型申请分配给两名科学和一名患者倡导者审稿人。审查结果将在行政核心中总结，并提交内部咨询委员会，以便就筹资问题提出建议。发展研究计划每年将资助3至4个项目，资助水平为每年5万美元。非常有前途的项目有资格获得额外一年的资助，但为了保持最大的灵活性，以吸引新的创新项目，每年将不超过一个项目的续期。发展研究项目的独特优势在于，它能够及时为高风险/试点项目提供重要的资金支持，以开发关键的初步数据，并通过执行委员会和内部咨询委员会的正式申请程序，提供灵活的机制，迅速响应新的倡议或令人兴奋的发现。或者通过RPCI-UPCI卵巢癌孢子首席研究员的自由支配基金获得更快但更少的资金。

The Developmental Research Program of the RPCI-UPCI Ovarian Cancer SPORE is a platform to support innovative, potentially high-risk/high-reward, investigator-initiated projects with the potential for maturation into translational ovarian cancer research projects that will transit basic and/or population research findings into research focused on human clinical specimens/patient populations. Furthermore, the funds of the Developmental Research Program will be leveraged by encouraging the development of the pilot projects into collaborative, multi-investigator, multi-institutional translational research programs, or as replacements for the Individual Research Projects of the RPCI-UPCI Ovarian Cancer SPORE. Therefore, the Developmental Research Program projects are the ultimate measure of the success of a SPORE, and form the base for future translational ovarian cancer research at the individual institutions since they are the springboard for the next generation of R01, P01, Consortium, and SPORE grants. Proposals from faculty with established ovarian cancer research programs, or faculty interested in transitioning to translational ovarian cancer research, will be evaluated by the Executive Committee for scientific merit. The Development Research Program Leaders will convene a NIH format study section and assign NIH R21- type applications to two scientific and one patient advocate reviewers. Review results will be summarized in the Administrative Core and submitted to the Internal Advisory Board for recommendations for funding. The Developmental Research Program will fund three to four projects per year at a funding level of $50,000 per year. Highly promising projects are eligible for an additional year of funding, but in order to maintain maximal flexibility in attracting new innovative projects, no more than one project per year will be a renewal. The unique strengths of the Developmental Research Program lie in its ability to provide significant financial support in a timely manner to high-risk/pilot projects to develop critical preliminary data, provide a flexible mechanism that can respond rapidly to new initiatives or exciting findings through a formal application procedure using the Executive Committee and Internal Advisory Board, or receive even quicker but lesser funds through an ad hoc award from the Discretionary Fund of the RPCI-UPCI Ovarian Cancer SPORE Principal Investigator.